Bristol-Myers shares could rise 25 pct on cancer drug-Barron's

NEW YORK, Feb 14 (Reuters) - Shares of Bristol-Myers Squibb could rise 25 percent within a year because of its cancer-fighting drug Opdivo, which some analysts see generating $8 billion to $9 billion in annual sales in five years, Barron's said in its latest edition.